BiomX Inc. Receives Notice of Compliance with NYSE American Continued Listing Standards

Group 1 - BiomX Inc. has regained compliance with all NYSE American continued listing standards as of December 10, 2024, resolving prior deficiencies noted on May 23, 2024 [1] - The company has demonstrated compliance for a period of two consecutive quarters as required by the NYSE American Company Guide [1] Group 2 - BiomX is a clinical-stage company focused on developing natural and engineered phage therapies targeting specific pathogenic bacteria for chronic diseases [2] - The company utilizes its BOLT platform to customize phage compositions against proprietary bacterial targets [2]